1
|
Ditsch N, Pochert N, Schneider M, Köpke M, Mattmer A, Hunstiger S, Sagasser J, Kahl H, Metz A, Reiger M, Neumann A, Banys-Paluchowski M, Untch M, Dannecker C, Jeschke U, Traidl-Hoffmann C, Kühn T. Cytokine identification in seroma fluid after mastectomy in breast cancer patients – first results of SerMa pilot study subgroup. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01583-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
2
|
Köpke BM, Garrido F, Vilsmaier T, Zati Zehni A, Kessler M, Mahner S, Chateau MC, Boissière-Michot F, Cavailles V, Dannecker C, Jeschke U, Ditsch N. Einfluss von Kernrezeptor-Expression und Einstrom von Tumor-infiltrierenden Lymphozyten auf das Überleben von Brustkrebspatientinnen. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- B M Köpke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - F Garrido
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - T Vilsmaier
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Zati Zehni
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Kessler
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M-C Chateau
- Institut Régional du Cancer de Montpellier (ICM), Montpellier, France
| | | | | | - C Dannecker
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - N Ditsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| |
Collapse
|
3
|
Schneider M, Köpke MB, Vilsmaier T, Zati Zehni A, Kessler M, Shao W, Mahner S, Cavailles V, Dannecker C, Jeschke U, Ditsch N. Die nukleäre Expression des Thyroidhormon-Rezeptors alpha 2 (TRα2) ist ein unabhängiger positiver prognostischer Marker für Patientinnen mit Mammakarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1749036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- M Schneider
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - MB Köpke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - T Vilsmaier
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - A Zati Zehni
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - M Kessler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - W Shao
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - S Mahner
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - V Cavailles
- IRCM-Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier
| | - C Dannecker
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| | - U Jeschke
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum der LMU, München
| | - N Ditsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Augsburg
| |
Collapse
|
4
|
Ditsch N, Schneider M, Pochert N, Ansorge N, Strieder A, Sagasser J, Kühn T, Neumann A, Reiger M, Traidl-Hoffmann C, Jeschke U, Dannecker C. 48P T-helper cell-driven immune response as an effect for seroma formation (SF) after mastectomy (ME) in breast cancer (BC) (SerMa pilot EUBREAST 5). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
5
|
Docheva V, Kolben T, Koelbl A, Gross E, Meindl A, Mahner S, Jeschke U, Ditsch N, Zeder-Göß C. Expression intensity and localization of BAP1 in hereditary breast cancer is associated with poor prognosis. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- V Docheva
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe – Ludwig-Maximilians-Universität München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe – Ludwig-Maximilians-Universität München
| | - A Koelbl
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe – Ludwig-Maximilians-Universität München
| | - E Gross
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe – Ludwig-Maximilians-Universität München
| | - A Meindl
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe – Ludwig-Maximilians-Universität München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe – Ludwig-Maximilians-Universität München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe – Ludwig-Maximilians-Universität München
- Klinik für Frauenheilkunde und Geburtshilfe, Universität Augsburg
| | - N Ditsch
- Klinik für Frauenheilkunde und Geburtshilfe, Universität Augsburg
| | - C Zeder-Göß
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe – Ludwig-Maximilians-Universität München
| |
Collapse
|
6
|
Heublein S, Jeschke U, Sattler C, Kuhn C, Hester A, Czogalla B, Trillsch F, Mahner S, Mayr D, Schmoeckel E, Ditsch N. Subcellular localization of thyroid hormone receptor beta is associated with grade, FIGO stage and disease outcome in ovarian cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Heublein
- Universitäts-Frauenklinik Heidelberg
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München
- Klinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität Augsburg
| | - C Sattler
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München
| | - C Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München
| | - D Mayr
- Pathologisches Institut der Ludwig-Maximilians-Universität München
| | - E Schmoeckel
- Pathologisches Institut der Ludwig-Maximilians-Universität München
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München
- Klinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität Augsburg
| |
Collapse
|
7
|
Trebo A, Ditsch N, Kuhn C, Heidegger H, Zeder-Göß C, Kolben T, Czogalla B, Schmoeckel E, Mahner S, Jeschke U, Hester A. Hohe Galectin-7 und niedrige Galectin-8 Expression und die Kombination aus beiden als prognostisch negative Marker für Brustkrebspatientinnen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Trebo
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
| | - N Ditsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
- Department of Obstetrics and Gynecology, University Hospital Augsburg
| | - C Kuhn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
| | - H Heidegger
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
| | - C Zeder-Göß
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
| | - T Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
| | - B Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
| | - E Schmoeckel
- Institute of Pathology, Faculty of Medicine, LMU Munich
| | - S Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
| | - U Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
- Department of Obstetrics and Gynecology, University Hospital Augsburg
| | - A Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
| |
Collapse
|
8
|
Berger L, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Ditsch N, Beyer S. Expression of H3K4me3 and H3K9ac in breast cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Berger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
9
|
Berger L, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Ditsch N, Beyer S. Expression von H3K4me3 und H3K9ac in Brustkrebs. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Berger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
10
|
Shao W, Kuhn C, Mayr D, Ditsch N, Mahner S, Harbeck N, Cavaillès V, Jeschke U, Sixou S. Untersuchungen zur differenzierten Expression von PPARγ, Cox-1 und Cox-2 beim Mammakarzinom. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- W Shao
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - C Kuhn
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - D Mayr
- Ludwig-Maximilians-Universität München, Pathologisches Institut, München, Deutschland
| | - N Ditsch
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - S Mahner
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - N Harbeck
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - V Cavaillès
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France; Université de Montpellier, France; Institut régional du Cancer de Montpellier, France
| | - U Jeschke
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - S Sixou
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
- Faculté des Sciences Pharmaceutiques, Université Paul Sabatier Toulouse III, Toulouse, France; Cholesterol Metabolism and Therapeutic Innovations, Cancer Research Center of Toulouse (CRCT), Université de Toulouse, CNRS, Toulouse, France
| |
Collapse
|
11
|
Salzmann B, Rahmeh M, Czogalla B, Kolben T, Kolben TM, Ditsch N, Mahner S, Jeschke U, Hester A. Der EP3-Antagonist L798,106 reduziert Proliferation und Migration von SK-BR-3 Mammakarzinom-Zellen. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- B Salzmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - M Rahmeh
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| |
Collapse
|
12
|
Hester A, Salzmann B, Rahmeh M, Kolben T, Kolben TM, Würstlein R, Harbeck N, Mahner S, Ditsch N, Jeschke U. EP1-/EP3-Agonist Sulproston und EP3-Antagonist L-798,106 reduzieren Proliferation und Migration von SKBR3-Mammakarzinomzellen. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- A Hester
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| | - B Salzmann
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| | - M Rahmeh
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| | - T Kolben
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| | - TM Kolben
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| | - R Würstlein
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| | - N Harbeck
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| | - S Mahner
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| | - N Ditsch
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| | - U Jeschke
- Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und CCC, Klinikum der Universität München, LMU München, München, Deutschland
| |
Collapse
|
13
|
Rippinger N, Haun MW, Fischer C, Rhiem K, Hübbel A, Grill S, Kiechle M, Cremer FW, Kast K, Nguyen HP, Ditsch N, Kratz P, Pfister S, Pajtler KW, Speiser D, Seitz S, Glimm H, Maatouk I, Hahne A, Sutter C, Schmutzler RK, Dikow N, Sohn C, Schott S. Prophylactic surgery among germline TP53 mutation carriers in Germany – a multicentric observational study. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- N Rippinger
- University Hospital Heidelberg, Department of Gynaecology and Obstetrics, Heidelberg, Deutschland
| | - MW Haun
- University Hospital Heidelberg, Department of General Internal Medicine and Psychosomatics, Heidelberg, Deutschland
| | - C Fischer
- University Hospital Heidelberg, Institute of Human Genetics, Heidelberg, Deutschland
| | - K Rhiem
- University Hospital of Cologne, Department of Gynaecology and Obstetrics, Cologne, Deutschland
| | - A Hübbel
- University Hospital of Cologne, Department of Gynaecology and Obstetrics, Cologne, Deutschland
| | - S Grill
- Klinikum rechts der Isar; Technical University of Munich, Department of Gynaecology and Centre for Hereditary Breast and Ovarian Cancer, Munich, Deutschland
| | - M Kiechle
- Klinikum rechts der Isar; Technical University of Munich, Department of Gynaecology and Centre for Hereditary Breast and Ovarian Cancer, Munich, Deutschland
| | - FW Cremer
- SYNLAB Centre for Human Genetics, Mannheim, Deutschland
| | - K Kast
- Medical Faculty and University Hospital Carl Gustav Carus, Technical University Dresden, Department of Gynaecology and Obstetrics, Dresden, Deutschland
- National Center for Tumor Diseases, Partner Site Dresden, Dresden, Deutschland
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Dresden, Deutschland
| | - HP Nguyen
- University Hospital of Tuebingen, Institute of Medical Genetics and Applied Genomics, Tuebingen, Deutschland
- University of Bochum, Department of Human Genetics, Bochum, Deutschland
| | - N Ditsch
- Ludwig-Maximilians University, University Hospital of Munich, Department of Gynaecology and Obstetrics, Munich, Deutschland
| | - P Kratz
- Hannover Medical School, Paediatric Haematology and Oncology, Hannover, Deutschland
| | - S Pfister
- Hopp Children's Cancer Centre at the NCT Heidelberg (KiTZ), Heidelberg, Deutschland
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Division of Paediatric Neurooncology, Heidelberg, Deutschland
- University Hospital Heidelberg, Department of Paediatric Oncology, Hematology and Immunology, Heidelberg, Deutschland
| | - KW Pajtler
- Hopp Children's Cancer Centre at the NCT Heidelberg (KiTZ), Heidelberg, Deutschland
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Division of Paediatric Neurooncology, Heidelberg, Deutschland
- University Hospital Heidelberg, Department of Paediatric Oncology, Hematology and Immunology, Heidelberg, Deutschland
| | - D Speiser
- University Hospital Charité Berlin, Department of Gynaecology and Obstetrics, Berlin, Deutschland
| | - S Seitz
- University Medical Centre Regensburg, Department of Gynaecology and Obstetrics, Regensburg, Deutschland
| | - H Glimm
- National Center for Tumor Diseases (NCT), Heidelberg, Deutschland
| | - I Maatouk
- University Hospital Heidelberg, Department of General Internal Medicine and Psychosomatics, Heidelberg, Deutschland
| | - A Hahne
- BRCA Network, Hannover, Deutschland
| | - C Sutter
- University Hospital Heidelberg, Department of Human Genetics, Heidelberg, Deutschland
| | - RK Schmutzler
- University Hospital of Cologne, Department of Gynaecology and Obstetrics, Cologne, Deutschland
| | - N Dikow
- University Hospital Heidelberg, Department of Human Genetics, Heidelberg, Deutschland
| | - C Sohn
- University Hospital Heidelberg, Department of Gynaecology and Obstetrics, Heidelberg, Deutschland
| | - S Schott
- University Hospital Heidelberg, Department of Gynaecology and Obstetrics, Heidelberg, Deutschland
| |
Collapse
|
14
|
Tremmel E, Vattai A, Hofmann S, Kuhn C, Ditsch N, Harbeck N, Jeschke U, Mahner S. Primäre Mammakarzinom Patientinnen (cM0) mit erhöhter Expression der L-DOPA Decarboxylase (DDC) im Primärtumor weisen ein verlängertes Gesamtüberleben auf. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- E Tremmel
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - S Hofmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - C Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - N Harbeck
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| |
Collapse
|
15
|
Vattai A, Tremmel E, Hofmann S, Kuhn C, Harbeck N, Ditsch N, Jeschke U, Mahner S. Einfluss von Thyronaminen auf die TAAR1 Expression sowie die Proliferation und Migration der Mammakarzinom Zelllinien MCF-7 und T47D. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - E Tremmel
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - S Hofmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - C Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - N Harbeck
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe und Brustzentrum der Ludwig-Maximilians Universität München, Campus Innenstadt und Campus Großhadern, München, Deutschland
| |
Collapse
|
16
|
Kölbl AC, Schlenk K, Gross E, Ditsch N, Mahner S, Jeschke U. Epithelial-mesenchymale Transition: ein möglicher Marker für Tumoraggressivität? Eine Real-Time PCR Analyse. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1655511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- AC Kölbl
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, Campus Großhadern, Marchioninistrasse 15, 81377 München; Campus Innenstadt, Maistrasse 11, 80337 München
| | - K Schlenk
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, Campus Großhadern, Marchioninistrasse 15, 81377 München; Campus Innenstadt, Maistrasse 11, 80337 München
| | - E Gross
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, Campus Großhadern, Marchioninistrasse 15, 81377 München; Campus Innenstadt, Maistrasse 11, 80337 München
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, Campus Großhadern, Marchioninistrasse 15, 81377 München; Campus Innenstadt, Maistrasse 11, 80337 München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, Campus Großhadern, Marchioninistrasse 15, 81377 München; Campus Innenstadt, Maistrasse 11, 80337 München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, Campus Großhadern, Marchioninistrasse 15, 81377 München; Campus Innenstadt, Maistrasse 11, 80337 München
| |
Collapse
|
17
|
Semmlinger A, Schoenfeldt V, Schmoeckel E, Mahner S, Jeschke U, Ditsch N. Prognostische Relevanz des EP3-Rezeptors bei sporadischem Brustkrebs. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1602357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- A Semmlinger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Großhadern, München, Deutschland
| | - V Schoenfeldt
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Innenstadt, München, Deutschland
| | - E Schmoeckel
- Institut für Pathologie LMU München, München, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Großhadern, München, Deutschland
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Innenstadt, München, Deutschland
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Großhadern, München, Deutschland
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Innenstadt, München, Deutschland
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Großhadern, München, Deutschland
| |
Collapse
|
18
|
Vattai A, Kuhn C, Hofmann S, Mahner S, Jeschke U, Ditsch N. Primäre Mammakarzinompatientinnen (M0) mit erhöhter Expression des Trace-amine associated receptors 1 (TAAR1) im Primärtumor weisen ein verlängertes Gesamtüberleben auf. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1602360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - C Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Hofmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| |
Collapse
|
19
|
Semmlinger A, von Schönfeldt V, Wolf V, Schmoeckel E, Mayr D, Meuter A, Mahner S, Jeschke U, Ditsch N. Abstract P2-05-23: EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aim: Prostaglandins are tissue hormones with a variety of biological effects and are mainly associated with infection and inflammation. However, elevated prostaglandin synthesis, especially of prostaglandin E2 (PGE2) caused by overexpression of cyclooxygenase-2 (COX-2), has also been associated with the development and progression of different kinds of cancer. Clinical trials have shown the potential of non-steroidal anti-inflammatory drugs or specific COX-2 inhibitors (coxibs) in prevention and treatment of malignant disease, as they reduce prostaglandin levels via inhibition of COX-2. Unfortunately, the clinical use of these drugs is limited due to their various side effects. PGE2 exerts its effects by signaling through four specific membrane-bound receptors, the EP-receptors 1-4. In recent research, the relevance of EP-receptors in carcinogenesis is investigated in the attempt to find a more specific target for the reduction of prostaglandin-effects without inducing side effects. This study evaluates the expression of EP3-receptor on breast cancer tissue and its correlation to progression and survival
Material and methods: A total of 277 sporadic breast cancer samples without primary distant metastases were immunohistochemically analyzed for EP3-receptor expression. Tissue samples were stained with primary anti-EP3 antibodies (monoclonal rabbit IgG). EP3-receptor-expression was quantified by the semi-quantitative immunoreactivity score (IRS); samples with an IRS ≥ 2 were scored as EP3 positive. Statistical analyses were performed with SPSS software using chi-squared test as well as Kaplan-Meier-estimates and Cox regression for survival analyses.
Results: EP3-receptor was expressed in 71.1 % of all cases. EP3-receptor expression did not correlate with clinicopathological parameters such as tumor size or lymph node status at primary diagnosis or with the expression of other immunohistochemical markers (estrogen and progesterone receptor, Her2). Distant metastasis occurred in 49.1 % of EP3 negative cases but only in 32.8 % of EP3 positive cases in an observation period of up to ten years (p = 0.03). EP3 receptor positive cases also showed significantly improved progression-free survival rates (overall [p = 0.01], ten years [p = 0.002] and five years [p = 0.04]). Furthermore, EP3-receptor positivity was associated with an improved overall survival rate (p = 0.002) and ten years survival rate (p = 0.001), whereas short-time survival rate (five years) did not differ between both EP3-groups (p = 0.10). In a multivariate analysis comparing all factors with significant influence in univariate testing, EP3-receptor could be confirmed as an independent factor.
Discussion: Our results show that EP3-receptor positivity is a relevant prognostic factor in sporadic breast cancer. Its correlation with a favorable course of disease is especially interesting as EP3 is known to regulate uPA, a well-known parameter which is – on the contrary - associated with unfavorable survival in breast cancer. Therefore, ongoing studies by our group aim to examine the correlation of EP3-receptor to the uPA/PAI1-pathway and to evaluate the possibility to target EP3-receptor in future anti-tumor therapy in breast cancer.
Citation Format: Semmlinger A, von Schönfeldt V, Wolf V, Schmoeckel E, Mayr D, Meuter A, Mahner S, Jeschke U, Ditsch N. EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-23.
Collapse
Affiliation(s)
| | | | - V Wolf
- LMU Munich, Munich, Bavaria, Germany
| | | | - D Mayr
- LMU Munich, Munich, Bavaria, Germany
| | - A Meuter
- LMU Munich, Munich, Bavaria, Germany
| | - S Mahner
- LMU Munich, Munich, Bavaria, Germany
| | - U Jeschke
- LMU Munich, Munich, Bavaria, Germany
| | - N Ditsch
- LMU Munich, Munich, Bavaria, Germany
| |
Collapse
|
20
|
Kolben T, Pieper K, Goess C, Degenhardt T, Ditsch N, Weissenbacher T, Weissenbacher E, Kolben T. IL-23, IFN-α, and IFN-β in the vaginal fluid of patients suffering from vulvovaginal candidosis. CLIN EXP OBSTET GYN 2017. [DOI: 10.12891/ceog3391.2017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
21
|
Kolben T, Pieper K, Goess C, Degnhardt T, Ditsch N, Weissenbacher T, Weissenbacher ER, Kolben TM. IL-23, IFN-α, and IFN-β in the vaginal fluid of patients suffering from vulvovaginal candidosis. CLIN EXP OBSTET GYN 2017; 44:7-10. [PMID: 29714856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
UNLABELLED Purpose of the investigation: Vulvovaginal candidosis (VVC) is a common vaginal infection affecting almost 75% of all women once per lifetime. Vaginal associated immunity is important in the protection against VVC. The purpose of this study was to evaluate a potential role of IL-23, IFN-α, and IFN-β in the local immune response against VVC. MATERIALS AND METHODS The study included 202 non-pregnant women; 71 patients with clinical symptoms of VVC and 131 asymptomatic patients served as control. IL-23, IFN-α, and IFN-β were measured in the vaginal fluid by ELISA. Microbiological cultures were used for Candida detection. RESULTS C. albicans was detected in 67.6% of patients, C. glabrata in 2 1.1% of patients, and 5.6% were infected with C. krusei or coinfected with C. albicans and C. krusei. Levels of IL-23 (p < 0.001) and IFN-β (p < 0.017) were significantly lower in the VVC group. IFN-α was elevated in the VVC group compared to the asymptomatic patients (p < 0.001). CONCLUSION IL-23 and IEFN-β seem to play a protective role against VVC. Decreased levels in VVC patients suggest a compromised local immune response at the time of occurrence of symptoms. In contrast, IFN-α seems to be released once the infection has occurred. These cytokines may be prospective targets in the treatment and prevention of primary and recurrent vaginal infections with Candida species.
Collapse
|
22
|
Göß C, Heublein S, Sattler C, Kolben T, Kolben TM, Burgmann M, Mayr D, Gallwas J, Burges A, Mahner S, Jeschke U, Ditsch N. Expression of nuclear hormone receptors in ovarian cancer. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
23
|
Kolben TM, Baltateanu K, Göß C, Ditsch N, Blume C, Gallwas J, Mahner S, Dannecker C, Kolben T. HPV-Impfung: Einstellung und Wissensstand unter Gynäkologen. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
24
|
Heublein S, Krebold R, Mayr D, Mahner S, Jeschke U, Ditsch N. Expression profiling of Thyroid-Hormone-Receptor alpha isoforms in breast cancer. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
25
|
Semmlinger A, Schönfeldt VV, Wolf V, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Ditsch N. Prognostic relevance of EP3-receptor expression in sporadic breast cancer tissue. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
26
|
Göß C, Kuhn R, Hertlein L, Fürst S, Bayer D, Kolben T, Kolben TM, Holdt L, Mahner S, Burges A, Ditsch N. Steroidhormonuntersuchungen bei sporadischem versus BRCA-mutiertem Ovarialkarzinom. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
27
|
Jalilova A, Dannecker C, Kolben TM, Kolben T, Ditsch N, Stepp H, Gallwas J. Optische Kohärenztomografie in Kombination mit einem Mikroskop zur Erkennung zervikaler intraepithelialer Dysplasien. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
28
|
Kolben TM, Dannecker C, Baltateanu K, Goess C, Starrach T, Semmlinger A, Ditsch N, Gallwas J, Mahner S, Friese K, Kolben T. HPV Vaccination: Attitude and Knowledge among German Gynecologists. Geburtshilfe Frauenheilkd 2016; 76:1074-1080. [PMID: 27761028 PMCID: PMC5065419 DOI: 10.1055/s-0042-112813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Revised: 07/17/2016] [Accepted: 07/18/2016] [Indexed: 10/20/2022] Open
Abstract
Purpose: In order to achieve a higher vaccination rate, education on HPV as well as options for prophylaxis performed by doctors is of great importance. One opportunity to increase the protection against HPV would be vaccinating boys. This study evaluated attitude and knowledge among German gynecologists regarding HPV vaccination, especially in boys. Material and Methods: A questionnaire with 42 questions about demographics, attitude and knowledge about HPV and HPV vaccination was sent to members of the German Society for Gynecology and Obstetrics (DGGG). Results: 998 out of 6567 addressed gynecologists participated. Knowledge about HPV, associated diseases and possible HPV vaccines was high among participants. The attitude towards vaccination in boys as well as girls was positive. Only 8.2 % refused to vaccinate their sons whereas 2.2 % refused to do this for their daughters. However, only few gynecologists vaccinated their daughters and sons against HPV. Main reason for girls was an age outside of vaccination guidelines; for boys it was the lack of cost coverage. Conclusion: The willingness of gynecologists to perform HPV vaccination in boys is as high as for girls. However, sons of gynecologists are only rarely vaccinated against HPV. Main reason is the lack of cost coverage. Vaccinating boys could decrease the disease burden in males, as well as protect women by interrupting ways of transmission. Since the main argument against vaccination of boys is only of financial nature, the necessity of a vaccination recommendation for boys needs to be re-evaluated taking into account the cost-reduced 2-dose vaccination scheme.
Collapse
Affiliation(s)
- T. M. Kolben
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - C. Dannecker
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - K. Baltateanu
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - C. Goess
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - T. Starrach
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - A. Semmlinger
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - N. Ditsch
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - J. Gallwas
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - S. Mahner
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - K. Friese
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - T. Kolben
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| |
Collapse
|
29
|
Heublein S, Krebold R, Mahner S, Jeschke U, Ditsch N. Expressionsprofil von Thyroid-Hormon-Rezeptor alpha Isoformen – potentielle prognostische Bedeutung bei Mammakarzinomen? Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1580672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
30
|
Kolben T, Schwarz TM, Goess C, Blume C, Degenhardt T, Engel J, Wuerstlein R, Ditsch N, Harbeck N, Kahlert S. Abstract P3-13-02: Surcigal management of ipsilateral breast tumor recurrence. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
PURPOSE
Approximately 10-15% of breast cancer patients treated by breast conserving surgery (BCS) and adjuvant radiotherapy (RT) will develop ipsilateral breast tumor recurrence (IBTR).
International guidelines suggest total mastectomy as treatment of choice for IBTR following lumpectomy and RT. Nevertheless, there is evidence that second BCS might be equally sufficient.
PATIENTS AND METHODS
Patients with IBTR diagnosed between 1990 and 2014 after BCS and RT were included (n=170).
34.1% women underwent secondary BCS, whereas 65.9% were treated by mastectomy. We determined predictive factors for time to local progression (TTP), disease free survival (DFS), and overall survival (OS) comparing these two groups.
RESULTS
Median follow-up after primary IBTR was 49 months (59 months for patients still alive at time of analysis). Five-year IBTR-free rate after secondary BCS was 77.6% (SD±6.1%) and 75.0% (SD±4.5%) for patients after mastectomy. Five-year DFS was 57.3% (SD±8.2%), and 61.9% (SD±5.5%), five-year OS was 84.7% (SD±5.8%), and 72.6% (SD±5.1%), respectively.
Prior adjuvant systemic therapy, muscular invasion, and skin infiltration were independent significant risk factors for a shorter TTP.
Additionally, lymphovascular infiltration (LVI) in the IBTR increased the risk for a shorter DFS.
LVI, muscular invasion, and skin infiltration were identified as independent significant risk factors for a shorter OS.
CONCLUSION
No significant difference in local control, DFS, and OS was seen between IBTR patients treated either by secondary BCS or mastectomy. Our data suggest that secondary BCS for IBTR patients after initial BCS and RT is feasible in selected patients.
Citation Format: Kolben T, Schwarz TM, Goess C, Blume C, Degenhardt T, Engel J, Wuerstlein R, Ditsch N, Harbeck N, Kahlert S. Surcigal management of ipsilateral breast tumor recurrence. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-13-02.
Collapse
Affiliation(s)
- T Kolben
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| | - TM Schwarz
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| | - C Goess
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| | - C Blume
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| | - T Degenhardt
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| | - J Engel
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| | - R Wuerstlein
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| | - N Ditsch
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| | - N Harbeck
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| | - S Kahlert
- Breast Center, Comprehensive Cancer Center of LMU, University Hospital Munich - Grosshadern, Ludwig-Maximilians-University, Munich, Germany; Munich Cancer Registry (MCR) of the Munich Cancer Center (MCC), Ludwig-Maximilians-University, Munich, Germany
| |
Collapse
|
31
|
Vattai A, Ziegelmüller B, Kost B, Kuhn C, Hofmann S, Bayer B, Anslinger K, Jeschke U, Ditsch N. Die Expression des Thyroid Hormon Rezeptors (THR) in Ersttrimester Plazenten sowie in Trophoblasttumor Zellen wird durch den Progesteron Rezeptor reguliert. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1555040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
32
|
Heublein S, Mayr D, Meindl A, Gallwas J, Dannecker C, Jeschke U, Ditsch N. Thyroidhormonrezeptoren in BRCA1 mutierten Mammakarzinomen – Potentielle prognostische Bedeutung und Modulation tumorbiologischer Eigenschaften. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1555086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
33
|
Heublein S, Page SK, Mayr D, Ditsch N, Burges A, Dannecker C, Jeschke U. Potentielle prognostische Relevanz des Kohlenhydrat-Tumorstammzell-Antigens TF1 (CD176) in Ovarialkarzinomen. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1555077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
34
|
Heublein S, Mayr D, Friese K, Jeschke U, Ditsch N. Vitamin-D-Rezeptor, Retinoid-X-Rezeptor und Peroxisom-Proliferator-aktivierter-Rezeptor-γ als Prognoseparameter für BRCA1 mutierte Brustkrebspatientinnen. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
35
|
Heublein S, Mayr D, Wiest I, Friese K, Jeschke U, Ditsch N. Immunreaktivität des Antikörpers PankoMabGEX™ ist ein unabhängiger Prognoseparameter für Brustkrebspatientinnen. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
36
|
Abstract
Zusammenfassung
Während mit der Entdeckung der Hochrisikogene „breast cancer 1“ (BRCA1) und „breast cancer 2“ (BRCA2) in den Jahren 1994/1995 die Erforschung des hereditären Mamma- und Ovarialkarzinoms zunächst beendet schien, belegen neuere Ergebnisse, dass das hereditäre Mamma- und Ovarialkarzinom eine extreme genetische Heterogenität aufweist. Die genetisch definierten Subtypen zeigen außerdem eine unterschiedliche phänotypische Ausprägung hinsichtlich der histopathologischen Charakteristika, des Krankheitsverlaufs und des Therapieansprechens. Dies erfordert eine Einbettung der Gendiagnostik in ein strukturiertes und standardisiertes Betreuungskonzept, das es erlaubt prospektive Daten zur Tumorinzidenz und zum Verlauf zu erfassen sowie in prospektiven Studien die Wertigkeit der verschiedenen diagnostischen, präventiven und neuen therapeutischen Optionen zu validieren. Das deutsche Konsortium widmet sich dieser Aufgabenstellung, um den betreffenden Familien effiziente Präventions- und Interventionsstrategien anbieten zu können. Dabei kommt der Zusammenarbeit mit der Selbsthilfe (http://www.BRCA-Netzwerk.de) mittlerweile eine große Bedeutung zu, die uns immer wieder vor Augen hält, wie wichtig es ist, den in diesem Artikel aufgeworfenen Fragestellungen nachzugehen.
Collapse
Affiliation(s)
- A. Meindl
- Aff1 grid.15474.33 0000000404772438 Abteilung Gyn. Tumorgenetik, München Klinikum rechts der Isar an der TU Ismaninger Str. 22 81675 München Deutschland
| | - K. Rhiem
- Aff2 grid.411097.a 000000008852305X Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinikum Köln Köln Deutschland
| | - C. Engel
- Aff3 grid.9647.c 0000000122309752 Institut für Medizinische Informatik, Statistik und Epidemiologie (IMISE) Universität Leipzig Leipzig Deutschland
| | - N. Ditsch
- Aff4 grid.411095.8 0000000404772585 Klinik und Poliklinik für Frauenheilkundeund Geburtshilfe Klinikum der Universität München, Campus Großhadern, LMU München Deutschland
| | - K. Kast
- Aff5 grid.412282.f Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Universitätsklinikum Carl Gustav Carus Dresden Deutschland
| | - E. Hahnen
- Aff2 grid.411097.a 000000008852305X Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinikum Köln Köln Deutschland
| | - R.K. Schmutzler
- Aff2 grid.411097.a 000000008852305X Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinikum Köln Köln Deutschland
| |
Collapse
|
37
|
Ditsch N, Vodermaier A, Hinke A, Burghardt S, Lenhard M, Löhrs B, Toth B, Von Koch F, Kahlert S, Bauerfeind I, Konecny GE, Loibl S, VON Minckwitz G, Untch M. Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer. Anticancer Res 2012; 32:3539-3545. [PMID: 22843943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND This post-hoc analysis aimed to compare an intense dose-dense sequential chemotherapy (DD-CT) and a conventionally-dosed chemotherapy (CD-CT) in the neoadjuvant AGO-1 study, focusing on the subgroup with inflammatory breast cancer (IBC). PATIENTS AND METHODS Out of 668 randomised patients, 101 patients presented with IBC. Patients received epirubicin followed by paclitaxel every 2 weeks (DD-CT) or simultaneously every 3 weeks (CD-CT). RESULTS No differences in pathological complete response rates were observed [odds ratio (OR)=1.27, p=0.33]. Most patients were scheduled for mastectomy before starting therapy; however, in 21.7% breast-conserving surgery was performed. Disease-free survival rates [Hazard Ratio (HR)=0.65; p=0.597] and overall survival rates (HR=1.40; p=0.327) were similar for both treatment arms. Patients with breast-conserving surgery had a significantly better outcome than patients treated with mastectomy (disease-free survival: HR=0.41; p=0.034 and overall survival: HR=0.09; p=0.003). CONCLUSION Patients with IBC benefited not from DD-CT but from breast-conserving surgery after neoadjuvant chemotherapy.
Collapse
Affiliation(s)
- N Ditsch
- Department of Obstetrics and Gynaecology, Ludwig Maximilians University, Marchioninistr. 15, 81377 Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Sattler C, Kuhn C, Hofmann S, Heublein S, Wiest I, Friese K, Lenhard M, Ditsch N, Jeschke U. Thyroidhormonrezeptor THRalpha2 Expression als Proliferationsfaktor in Ovarial-Karzinomen. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1318585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
39
|
Ditsch N, Mayr D, Lenhard M, Kolben T, Strauss C, Gallwas J, Himsl J, Weissenbacher T, Harbeck N, Friese K, Jeschke U. Immunohistochemical correlation of thyroid hormone receptors (TR), retinoid x receptor (RXR), peroxisome proliferators-activated receptor (PPAR), the vitamin D receptor (VDR) and estrogen-/progesterone receptor (ER/PR) in breast carcinoma. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1318576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
40
|
Hancke K, Toth B, Igl W, Ramsauer B, Bühren A, Wöckel A, Jundt K, Ditsch N, Gingelmaier A, Rhiem K, Vetter K, Friese K, Kreienberg R. Career and Family - Are They Compatible?: Results of a Survey of Male and Female Gynaecologists in Germany. Geburtshilfe Frauenheilkd 2012; 72:403-407. [PMID: 25298544 DOI: 10.1055/s-0031-1298393] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2011] [Revised: 02/14/2012] [Accepted: 03/01/2012] [Indexed: 10/28/2022] Open
Abstract
Purpose: Nowadays, most gynaecologists are female and the compatibility of job-related career and family life is an upcoming issue. The working group "Gender and Career" of the German Society for Gynaecology and Obstetrics (DGGG) designed a survey to reflect the present situation with a focus on the compatibility of career and family. Material and Methods: A web-based 74-item survey was filled out by members of the DGGG. In total, there were 1037 replies, 75 % female (n = 775) and 25 % male (n = 261) gynaecologists. Results: 62 % of the female and 80 % of the male respondents had already finished their doctoral theses and 2 % female and 13 % male had finished their PhD. Mean number of children was 1.06 (SD 1.08) in female and 1.68 (SD 1.34) in male gynaecologists. The majority of females desired day care for their children, but only 5 to 13 % of employers offer any day care. 88 % of the female and 72 % of the male physicians think that job-related career and family are not compatible. Conclusion: The majority of female gynaecologists wished to have professional child care, but most employers or other institutions do not offer this. This might be one of the reasons why career and family appear incompatible.
Collapse
Affiliation(s)
- K Hancke
- University Gynaecological Hospital, Ulm
| | - B Toth
- Gynaecological Endocrinology and Fertility Disorders, Ruprecht-Karls-Universität Heidelberg, Heidelberg
| | - W Igl
- Wilmar Igl Statistical Consulting, Berlin
| | | | - A Bühren
- Surgery for Psychosomatic Medicine and Psychotherapy, Murnau
| | - A Wöckel
- University Gynaecological Hospital, Ulm
| | - K Jundt
- Department and Outpatient Clinic for Gynaecology and Obstetrics, Hospital of the Ludwig-Maximilians-Universität Munich, München
| | - N Ditsch
- Department and Outpatient Clinic for Gynaecology and Obstetrics, Hospital of the Ludwig-Maximilians-Universität Munich, München
| | - A Gingelmaier
- Department and Outpatient Clinic for Gynaecology and Obstetrics, Hospital of the Ludwig-Maximilians-Universität Munich, München
| | - K Rhiem
- University Gynaecological Hospital, Cologne
| | - K Vetter
- Vivantes Klinikum Neukölln, Berlin
| | - K Friese
- Department and Outpatient Clinic for Gynaecology and Obstetrics, Hospital of the Ludwig-Maximilians-Universität Munich, München
| | | |
Collapse
|
41
|
Ditsch N, Mayr D, Toth B, Hasmüller S, Lenhard M, Weissenbacher T, Himsl I, Friese K, Jeschke U. 311 Vitamin D Receptor and Prognosis in Breast Cancer. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70377-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Ditsch N, Vrekoussis T, Lenhard M, Rühl I, Gallwas J, Weissenbacher T, Friese K, Mayr D, Makrigiannakis A, Jeschke U. Retinoid X receptor alpha (RXRα) and peroxisome proliferator-activated receptor gamma (PPARγ) expression in breast cancer: an immunohistochemical study. In Vivo 2012; 26:87-92. [PMID: 22210720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND/AIM The role of retinoid X receptor alpha (RXRα) and peroxisome proliferator-activated receptor gamma (PPARγ) in breast cancer has been well studied in vitro. The aim of the study was to assess the presence of these molecules in human breast cancer specimens and correlate them with major clinicopathological features. PATIENTS AND METHODS Tissue sections from 82 breast cancer cases clustered according to histological grade, lymph node (LN) and hormone receptor (HR) status were assessed by immunohistochemistry for RXRα and PPARγ. RESULTS RXRα was found to be strongly and moderately expressed in 11 (14.10%) and 33 (42.31%) cases, respectively. PPARγ was found to be strongly and moderately expressed in 33 (41.25%) and 25 (31.25%) cases, respectively. Only RXRα expression was inversely correlated with histological grade. Surprisingly, significantly elevated PPARγ expression was found in cases with positive LN status. Survival analysis did not yield significant results. CONCLUSION Our data support the current thesis of RXRα being a potential target for feature molecular interventions.
Collapse
Affiliation(s)
- N Ditsch
- Department of Obstetrics and Gynecology, Grosshadern Campus, Ludwig Maximilians University of Munich, Munich, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Lenhard M, Tsvilina A, Schumacher L, Kupka M, Ditsch N, Mayr D, Jeschke U, Friese K. Gonadotropinexpression im Ovarialkarzinomgewebe: Korrelation mit Histologie und Überleben. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
44
|
Rhiem K, Engel C, Graeser M, Kiechle M, Ditsch N, Mundhenke C, Kreienberg R, Tio J, Golatta M, Hönig A, Gadzicki D, Speiser D, Kast K, Briest S, Meindl A, Schmutzler R. Kontralaterales Mammakarzinom-Risiko bei BRCA1/2-negativen Patientinnen mit familiärer Hochrisikosituation. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
45
|
Rhiem K, Engel C, Graeser M, Janni W, Kiechle M, Ditsch N, Mundhenke C, Kreienberg R, Tio J, Golatta M, Honig A, Gadzicki D, Speiser D, Kast K, Briest S, Meindl A, Schmutzler R. Contralateral breast cancer risk in patients with familial breast cancer who tested negative for BRCA1 and BRCA2. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Lenhard M, Tsvilina A, Schumacher L, Kupka M, Ditsch N, Mayr D, Jeschke U, Friese K. Korrelation des Humanen Choriongonadotropin mit Tumorstadium, Grad und Überleben von Ovarialkarzinompatientinnen. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1278557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
47
|
Ditsch N, Lenhard M, Himsl I, Weissenbacher T, Friese K, Mayr D, Jeschke U. Nachweis von Schilddrüsenhormonrezeptoren beim Mammakarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1278616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
48
|
Gallwas J, Ditsch N, Hillemanns P, Friese K, Thaler C, Dannecker C. The significance of HPV in the follow-up period after treatment for CIN. EUR J GYNAECOL ONCOL 2010; 31:27-30. [PMID: 20349777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
PURPOSE OF INVESTIGATION High-risk anogenital human papillomavirus (HPV) infections are causally related to cervical cancer. Successful treatment of cervical intraepithelial neoplasia (CIN) results in complete eradication of HPV in most cases. There is an increasing interest regarding the role of HPV testing in the follow-up period after treatment for CIN. PATIENTS AND METHODS This retrospective study includes 107 women who underwent conization for histologically verified CIN. All of them had HPV testing pre- and postoperatively. HPV testing was carried out using a hybrid capture assay (HC2). The mean follow-up period was 21.4 months (range 2-76 months). The data were analyzed with respect to success of conization, HPV persistence/recurrence and CIN recurrence. Sensitivity, specificity and negative predictive value (NPV) of HPV testing were assessed and compared to the cytological results. RESULTS Preoperatively, 97 of 107 women were HPV positive. Ninety-seven conizations showed negative resection margins with 86 women becoming HPV negative. In the following months, nine of these HPV negative women became HPV positive again. Out of ten conizations with positive resection margins, six women became HPV negative. Recurrent CIN 2/3 lesions were observed in 11 women, nine of whom had persistent positive HPV testing throughout the entire study period. Regarding CIN recurrence HPV testing showed a sensitivity of 93%, a specificity of 85% and a NPV of 99%. CONCLUSIONS The sensitivity of HPV testing concerning persistent or recurrent CIN as well as the NPV are high. The present data suggest that HPV testing should be integrated in a follow-up algorithm after treatment for CIN by conization.
Collapse
Affiliation(s)
- J Gallwas
- Department of Obstetrics and Gynecology, University of Munich, Munich, Germany
| | | | | | | | | | | |
Collapse
|
49
|
Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S, Neuhausen SL, Ding YC, Couch FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai P, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Weerasooriya N, Gerdes AM, Thomassen M, Cruger DG, Caligo MA, Friedman E, Kaufman B, Laitman Y, Cohen S, Kontorovich T, Gershoni-Baruch R, Dagan E, Jernström H, Askmalm MS, Arver B, Malmer B, Domchek SM, Nathanson KL, Brunet J, Ramón Y Cajal T, Yannoukakos D, Hamann U, Hogervorst FBL, Verhoef S, Gómez García EB, Wijnen JT, van den Ouweland A, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Cook J, Hodgson S, Morrison PJ, Douglas F, Godwin AK, Sinilnikova OM, Barjhoux L, Stoppa-Lyonnet D, Moncoutier V, Giraud S, Cassini C, Olivier-Faivre L, Révillion F, Peyrat JP, Muller D, Fricker JP, Lynch HT, John EM, Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D, Singer CF, Gschwantler-Kaulich D, Pfeiler G, Spiess AC, Hansen TVO, Johannsson OT, Kirchhoff T, Offit K, Kosarin K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Varon-Mateeva R, Schaefer D, Froster UG, Caldes T, de la Hoya M, McGuffog L, Antoniou AC, Nevanlinna H, Radice P, Benítez J. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br J Cancer 2009; 101:2048-54. [PMID: 19920816 PMCID: PMC2795432 DOI: 10.1038/sj.bjc.6605416] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Background: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. Methods: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach. Results: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93–1.04, P=0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89–1.06, P=0.5) mutation carriers. Conclusion: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.
Collapse
Affiliation(s)
- A Osorio
- Human Genetics Group, Spanish National Cancer Research Centre, C/Melchor Fernández Almagro 3, 28029 Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Kuemper C, Burges A, Hillemanns P, Mueller-Egloff S, Lenhard M, Ditsch N, Strauss A. Supraclavicular lymph node metastases of unknown origin: HPV-typing identifies the primary tumour. Eur J Cancer Care (Engl) 2009; 18:606-11. [PMID: 19549285 DOI: 10.1111/j.1365-2354.2008.00937.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Cancers of unknown primary origin (CUP) account for 0.5-10% of all malignancies. CUP patients with metastases have a median survival of approximately 6 months, despite therapy. Identification of the primary tumour site may offer the opportunity of a specific and more efficient treatment. The case of a 45-year-old woman with supraclavicular lymph node metastases of a squamous cell CUP is reported. A staging laparoscopy with multiple biopsies and a loop diathermy excision of the cervix were performed. Human papillomavirus (HPV)-testing in the tissues revealed the tumour cells as metastases of an occult cervical cancer. Primary platin-based chemotherapy combined with paclitaxel leads to a complete apparative remission. Twelve months later, staging positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in combination with computed tomography identified an isolated left renal lymph node metastasis. The patient received targeted radiation therapy, combined with cisplatin. To date, 19 months after diagnosis, she is doing well without any evidence of disease. The presented case report addresses the difficulties involving the identification of CUP. HPV-DNA is found in over 95% of cervical cancers. As the presented case illustrates, testing for this virus DNA in human tissues can be a useful diagnostic tool in patients with CUP where cervical cancer is the possible primary tumour.
Collapse
Affiliation(s)
- C Kuemper
- Department of Obstetrics and Gynecology, Kiel University Hospital, Arnold-Heller-Strasse 3, 24105 Kiel, Germany.
| | | | | | | | | | | | | |
Collapse
|